NXTC Logo

NextCure, Inc. (NXTC) 

NASDAQ$0.5782
Market Cap
$16.19M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
749 of 924
Rank in Industry
424 of 527

NXTC Insider Trading Activity

NXTC Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$00–
Sells
$00–

Related Transactions

No records found

About NextCure, Inc.

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; â€¦

Insider Activity of NextCure, Inc.

Over the last 12 months, insiders at NextCure, Inc. have bought $0 and sold $0 worth of NextCure, Inc. stock.

On average, over the past 5 years, insiders at NextCure, Inc. have bought $0 and sold $0 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 150,000 shares for transaction amount of $5.51M was made by Sofinnova Venture Partners IX, L.P. (10 percent owner) on 2019‑11‑15.

List of Insider Buy and Sell Transactions, NextCure, Inc.

2019-11-15PurchaseSofinnova Venture Partners IX, L.P.10 percent owner
150,000
0.9742%
$36.75$5.51M-7.91%
2019-05-13PurchaseORBIMED ADVISORS LLC
700,000
4.0096%
$15.00$10.5M+82.16%
2019-05-13PurchaseKhuong Chau Quangdirector
350,000
2.0048%
$15.00$5.25M+82.16%
2019-05-13PurchaseSofinnova Venture Partners IX, L.P.10 percent owner
400,000
2.2912%
$15.00$6M+82.16%
2019-05-13PurchaseSHANNON TIMOTHY Mdirector
50,000
0.2864%
$15.00$750,000+82.16%
2019-05-13PurchaseCANAAN X L.P.10 percent owner
50,000
0.2864%
$15.00$750,000+82.16%
2019-05-13PurchaseXu Stelladirector
125,000
0.716%
$15.00$1.88M+82.16%
Total: 7

Insider Historical Profitability

<0.0001%
ORBIMED ADVISORS LLC
2711013
9.6799%
$1.57M10
Khuong Chau Quangdirector
2711013
9.6799%
$1.57M10
Sofinnova Venture Partners IX, L.P.10 percent owner
2671856
9.5401%
$1.54M20<0.0001%
SHANNON TIMOTHY Mdirector
2254442
8.0497%
$1.3M10
CANAAN X L.P.10 percent owner
2254442
8.0497%
$1.3M10

Historical Insider Profitability vs. Competitors

$85,897,100
36
2.47%
$17.48M
$217,684
34
1.61%
$14.84M
$4,368,362
28
-22.35%
$17.38M
$550,893
22
-22.12%
$14.77M
$555,628
21
43.52%
$18.45M

NXTC Institutional Investors: Active Positions

Increased Positions13+22.81%2M+13.3%
Decreased Positions19-33.33%3M-21.42%
New Positions7New2MNew
Sold Out Positions6Sold Out3MSold Out
Total Postitions51-10.53%15M-8.12%

NXTC Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Sofinnova Investments, Inc.$1,841.009.54%2.67M00%2024-12-31
Affinity Asset Advisors, Llc$1,586.008.22%2.3M00%2024-12-31
Citigroup Inc$957.004.96%1.39M+1MNew2024-12-31
Orbimed Advisors Llc$786.004.08%1.14M00%2024-12-31
Vanguard Group Inc$680.003.53%987,32400%2024-12-31
Blackrock, Inc.$501.002.6%727,579-2,257-0.31%2024-12-31
Tang Capital Management Llc$482.002.5%700,000+47,614+7.3%2024-12-31
Cable Car Capital, Lp$424.002.2%615,87800%2024-12-31
Renaissance Technologies Llc$358.001.86%519,300+113,300+27.91%2024-12-31
Acadian Asset Management Llc$337.001.74%488,44000%2024-12-31

Financial Ratios

Summary
Comparison with Competitors

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
1Strong BuyBuyHoldSellStrong SellNXTCHighAverageLowSeries 4